Clinical Trial: NCT05150652
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Irada Ibrahim-zada |
| Information Provided By: | University of Kentucky |
| Last Update Posted: | 2026-08-31 |
Study Overview
Brief Summary
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Official Title
Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Conditions
Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Intervention / Treatment
- Drug: Anastrozole 1mg
- Drug: Letrozole 2.5mg
- Drug: Exemestane 25 mg
- Drug: Tamoxifen
Other Study ID Numbers
- MCC-21-BRE-54
Start Date (Actual)
2022-02-18
Primary Completion Date (Actual)
2025-12-09
Study Completion Date (Actual)
2026-06-10
Enrollment (Actual)
8
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Irada Ibrahim-zada |
| Information Provided By: | University of Kentucky |
| Last Update Posted: | 2026-08-31 |
Study Overview
Brief Summary
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Official Title
Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Conditions
Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Intervention / Treatment
- Drug: Anastrozole 1mg
- Drug: Letrozole 2.5mg
- Drug: Exemestane 25 mg
- Drug: Tamoxifen
Other Study ID Numbers
- MCC-21-BRE-54
Start Date (Actual)
2022-02-18
Primary Completion Date (Actual)
2025-12-09
Study Completion Date (Actual)
2026-06-10
Enrollment (Actual)
8
Study Type
Interventional
Phase
Phase 2